Ming Tang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6099416/publications.pdf Version: 2024-02-01



MING TANG

1 Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. Cancer Cell, 2017, 32, 204-220.e15. 2 Systematic analysis of telomere length and somatic alterations in 31 cancer types. Nature Genetics, 2017, 49, 349-357. 3 KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell, 2019, 35, 559-572.e7. 4 Suppression of Type IIFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Research, 2017, 77, 839-850. 5 TumorFusions: an integrative resource for cancer-associated transcript fusions. Nucleic Acids Research, 2018, 46, D1144-D1149. 6 Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature, 2017, 542, 484-488. 7 KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer. Cancer Cell, 2020, 37, 599-617.e7. 8 The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations. Cancer Cell, 2018, 34, 197-210.e5. 9 Integrative analyses of single-cell transcriptome and regulome using MAESTRO. Genome Biology, 2020, 21, 198. 10 Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer. Cancer Discovery, 2020, 10, 1058-1077. 11 Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia. Leukemia, 2019, 33, 931-944.	16.8 21.4 21.4 16.8 0.9 14.5	642 476 353 195
 2017, 49, 349-357. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell, 2019, 35, 559-572.e7. Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Research, 2017, 77, 839-850. TumorFusions: an integrative resource for cancer-associated transcript fusions. Nucleic Acids Research, 2018, 46, D1144-D1149. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature, 2017, 542, 484-488. KMT2D Deficiency Impairs Super-Enhancers to Confer a Clycolytic Vulnerability in Lung Cancer. Cancer Cell, 2020, 37, 599-617.e7. The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations. Cancer Cell, 2018, 34, 197-210.e5. Integrative analyses of single-cell transcriptome and regulome using MAESTRO. Genome Biology, 2020, 21, 198. Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer. Cancer Discovery, 2020, 10, 1058-1077. Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia. Leukemia, 2019, 33, 931-944. Enhancer Reprogramming Confers Dependence on Clycolysis and IGF Signaling in KMT2D Mutant 	er 16.8 0.9	353
 Cell, 2019, 35, 559-572.e7. Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Research, 2017, 77, 839-850. TumorFusions: an integrative resource for cancer-associated transcript fusions. Nucleic Acids Research, 2018, 46, D1144-D1149. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature, 2017, 542, 484-488. KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer. Cancer Cell, 2020, 37, 599-617.e7. The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations. Cancer Cell, 2018, 34, 197-210.e5. Integrative analyses of single-cell transcriptome and regulome using MAESTRO. Genome Biology, 2020, 21, 198. Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer. Cancer Discovery, 2020, 10, 1058-1077. Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia. Leukemia, 2019, 33, 931-944. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant 	0.9	
 ⁴ Overcome by Radiotherapy. Cancer Research, 2017, 77, 839-850. ⁵ TumorFusions: an integrative resource for cancer-associated transcript fusions. Nucleic Acids Research, 2018, 46, D1144-D1149. ⁶ Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature, 2017, 542, 484-488. ⁷ KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer. Cancer Cell, 2020, 37, 599-617.e7. ⁸ The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations. Cancer Cell, 2018, 34, 197-210.e5. ⁹ Integrative analyses of single-cell transcriptome and regulome using MAESTRO. Genome Biology, 2020, 21, 198. ¹⁰ Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer. Cancer Discovery, 2020, 10, 1058-1077. ¹¹ Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia. Leukemia, 2019, 33, 931-944. ¹² Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant 		195
 Research, 2018, 46, DI144-D1149. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature, 2017, 542, 484-488. KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer. Cancer Cell, 2020, 37, 599-617.e7. The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations. Cancer Cell, 2018, 34, 197-210.e5. Integrative analyses of single-cell transcriptome and regulome using MAESTRO. Genome Biology, 2020, 21, 198. Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer. Cancer Discovery, 2020, 10, 1058-1077. Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia. Leukemia, 2019, 33, 931-944. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant 	14.5	
 542, 484-488. KMT2D Deficiency Impairs Super-Enhancers to Confer a Clycolytic Vulnerability in Lung Cancer. Cancer Cell, 2020, 37, 599-617.e7. The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations. Cancer Cell, 2018, 34, 197-210.e5. Integrative analyses of single-cell transcriptome and regulome using MAESTRO. Genome Biology, 2020, 21, 198. Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer. Cancer Discovery, 2020, 10, 1058-1077. Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia. Leukemia, 2019, 33, 931-944. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant 		179
 Cell, 2020, 37, 599-617.e7. The Tandem Duplicator Phenotype Is a Prevalent Genome-Wide Cancer Configuration Driven by Distinct Gene Mutations. Cancer Cell, 2018, 34, 197-210.e5. Integrative analyses of single-cell transcriptome and regulome using MAESTRO. Genome Biology, 2020, 21, 198. Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer. Cancer Discovery, 2020, 10, 1058-1077. Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia. Leukemia, 2019, 33, 931-944. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant 	27.8	173
 Gene Mutations. Cancer Cell, 2018, 34, 197-210.e5. Integrative analyses of single-cell transcriptome and regulome using MAESTRO. Genome Biology, 2020, 21, 198. Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer. Cancer Discovery, 2020, 10, 1058-1077. Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia. Leukemia, 2019, 33, 931-944. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant 	16.8	137
 21, 198. Tumor Microenvironment Remodeling Enables Bypass of Oncogenic KRAS Dependency in Pancreatic Cancer. Cancer Discovery, 2020, 10, 1058-1077. Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia. Leukemia, 2019, 33, 931-944. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant 	16.8	130
 Cancer. Cancer Discovery, 2020, 10, 1058-1077. Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia. Leukemia, 2019, 33, 931-944. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant 	8.8	126
 phenotype in acute myeloid leukemia. Leukemia, 2019, 33, 931-944. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant 	9.4	87
	7.2	39
Melanoma. Cell Reports, 2020, 55, 100255.	6.4	39
Fast alignment and preprocessing of chromatin profiles with Chromap. Nature Communications, 2021, 12, 6566.	12.8	39
Positive Regulation of Transcription by Human ZMYND8 through Its Association with P-TEFb Complex. Cell Reports, 2018, 24, 2141-2154.e6.	6.4	30
¹⁵ Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer. Gut, 2022, 71, 938-949.	12.1	25
An Integrated Platform for Genome-wide Mapping of Chromatin States Using High-throughput ChIP-sequencing in Tumor Tissues. Journal of Visualized Experiments, 2018, , .	0.3	24
 P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis. Oncogene, 2021, 40, 6049-6056. 	5.9	19
18 Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy. Cell Reports, 2021, 36, 109410.	6.4	17

Ming Tang

#	Article	IF	CITATIONS
19	The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nature Communications, 2021, 12, 7081.	12.8	16
20	Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). Clinical Cancer Research, 2021, 27, 5038-5048.	7.0	13
21	Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. Acta Neuropathologica, 2021, 142, 565-590.	7.7	12
22	Comprehensive Characterizations of Immune Receptor Repertoire in Tumors and Cancer Immunotherapy Studies. Cancer Immunology Research, 2022, 10, 788-799.	3.4	10
23	Cross-Site Concordance Evaluation of Tumor DNA and RNA Sequencing Platforms for the CIMAC-CIDC Network. Clinical Cancer Research, 2021, 27, 5049-5061.	7.0	6
24	A Molecular Take on Malignant Rhabdoid Tumors. Trends in Cancer, 2016, 2, 217-218.	7.4	5
25	CHIPS: A Snakemake pipeline for quality control and reproducible processing of chromatin profiling data. F1000Research, 0, 10, 517.	1.6	4
26	Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 172.	8.6	2
27	EPIG-05RADIORESISTANCE OF PODOPLANIN-EXPRESSING GLIOMA STEM CELLS IS ASSOCIATED WITH EZH2-DRIVEN POLYCOMB REPRESSIVE COMPLEX ACTIVITY. Neuro-Oncology, 2015, 17, v87.1-v87.	1.2	0